



Explore the *Pawsitive* Impact

See how **Librela** for dogs and **Solensia** for cats could help improve quality of life for your patients with osteoarthritis (OA) pain.



Treatment with Librela for dogs and Solensia for cats for the control of OA pain improved quality of life after 2 months of injections¹



As reported by pet owners, the quality of life for dogs taking Librela showed a significant improvement in the following areas¹:



Energy and enthusiasm



Happiness and contentedness



Calmness and relaxation



Activity and comfort

As reported by pet owners, the quality of life for cats taking Solensia showed a significant improvement in the following areas¹:



Vitality



Physical well-being



Emotional well-being



Comfort




Results for this study were determined using **VetMetrica™**, an assessment tool that measures the quality of life and health-related quality of life for dogs and cats through behavior-related questionnaires completed by pet owners. It determines the physical, emotional, behavioral, and environmental health of dogs and cats and examines how health conditions and treatments affect the animal's daily functioning and well-being.¹

Learn more about how Librela and Solensia could make a difference for your canine and feline patients at LibrelaVetTeam.com and SolensiaVetTeam.com.


Librela Helped Improve Quality of Life in Dogs With OA Pain¹

Health-related quality-of-life (HRQL) scores in dogs receiving Librela injections and evaluated for 70 days (N=75)



Solensia Helped Improve Quality of Life in Cats With OA Pain¹

Health-related quality-of-life scores in cats receiving Solensia to control osteoarthritis (OA) pain for 10 weeks (N=56)



LIBRELA IMPORTANT SAFETY INFORMATION: Librela is for use in dogs only. Women who are pregnant, trying to conceive or breastfeeding should take extreme care to avoid self-injection. Hypersensitivity reactions, including anaphylaxis, could potentially occur with self-injection. Librela should not be used in breeding, pregnant, or lactating dogs. Librela should not be administered to dogs with known hypersensitivity to bedinvetmab. Adverse events reported post-approval include ataxia (lack of balance/coordination), anorexia (loss of appetite), lethargy (tiredness), emesis (vomiting), and polydipsia (increased drinking). The most common adverse events reported in a clinical study were urinary tract infections, bacterial skin infections and dermatitis (skin irritation/inflammation). For complete safety information, refer to the full prescribing information at [LibrelaPI.com](https://www.librelapi.com).

SOLENSIA IMPORTANT SAFETY INFORMATION: For use in cats only. Women who are pregnant, trying to conceive or breastfeeding should take extreme care to avoid self-injection. Hypersensitivity reactions, including anaphylaxis, could potentially occur with self-injection. Solensia should not be used in breeding cats or in pregnant or lactating queens. Solensia should not be administered to cats with known hypersensitivity to frunevetmab. The most common adverse events reported in a clinical study were vomiting and injection site pain. Solensia may be associated with scabbing of the head and neck, dermatitis, and pruritus. See full Solensia Prescribing Information at [SolensiaPI.com](https://www.solensiaPI.com).

Reference: 1. Reid J, Gildea E, Davies V, Thompson J, Scott M. Measuring the effect of the anti-nerve growth factor antibodies bedinvetmab and frunevetmab on quality of life in dogs and cats with osteoarthritis using a validated health-related quality of life outcome measure: an observational real-world study. *Front Vet Sci.* 2024;11:1395360. doi:10.3389/fvets.2024.1395360

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. © 2026 Zoetis Services LLC. All rights reserved. LIB-00781R1